The importance of the circadian/melatonin signal in suppressing the metastatic progression of breast and other cancers has been reported by numerous laboratories including our own. Currently, the mechanisms underlying the anti-metastatic actions of melatonin have not been well established. In the present study, the anti-metastatic actions of melatonin were evaluated and compared on the ERα-negative, Her2-positive SKBR-3 breast tumor cell line and ERα-positive MCF-7 cells overexpressing a constitutively active HER2.1 construct (MCF7Her2.1 cells). Activation of Her2 is reported to induce the expression and/or phosphorylationdependent activation of numerous kinases and transcription factors that drive drug resistance and metastasis in breast cancer. A key signaling node activated by the Her2/Mapk/Erk pathway is Rsk2, which has been shown to induce numerous signaling pathways associated with the development of epithelial-to-mesenchymal transition (EMT) and metastasis including: Creb, Stat3, cSrc, Fak, Pax, Fascin, and actin polymerization. The data demonstrate that melatonin (both endogenous and exogenous) significantly represses this invasive/metastatic phenotype through a mechanism that involves the suppression of EMT, either by promoting mesenchymalto-epithelial transition (MET), and/or by inhibiting key signaling pathways involved in later stages of metastasis. These data, combined with our earlier in vitro studies, support the concept that maintenance of elevated and extended duration of nocturnal melatonin levels plays a critical role in repressing the metastatic progression of breast cancer.
Introduction
Breast cancer, the most commonly diagnosed cancer in women, represents 29% of all new cases in 2013 (1) . Although most breast cancers are diagnosed at relatively early stages, nearly 30% of them will eventually develop metastasis despite treatment (2) . Metastasis, a hallmark of cancer, is the principal cause of death from breast cancer (3) . However, the molecular mechanisms underlying the development of metastatic breast cancer remain unclear, and defining such mechanisms is of paramount importance. It is well known that activation of various signaling pathways promotes the epithelial-to-mesenchymal transition (EMT) and development of a metastatic phenotype in breast cancer cells (4) . Human epidermal growth factor receptor 2 (Her2 or ErbB2) is a type I transmembrane receptor tyrosine kinase that belongs to the epidermal growth factor receptor (Egfr) family (5) . Two additional members, Her3 and -4, complete this family. Overexpression of Her2 at the cell membrane has been reported to underlie a clinically aggressive metastatic form of breast cancer termed ErbB2/Her2-positive (6) (7) (8) . Although Her2 is an orphan receptor that does not bind ligand, its canonical mechanism of activation includes homodimerization or heterodimerization with other members of the Her/ErbB family to stimulate its tyrosine (Tyr) kinase activity to induce the activation of downstream signaling pathways (8) . In mammalian cells, various mitogenic stimuli, including epidermal growth factor (Egf), induce a Ras-dependent, mitogen-activated, and extracellular signalregulated kinase (Mapk/Erk) cascade that results in the transcriptional activation of immediate early response genes including the Ser/Thr kinase ribosomal S6 kinase (Rsk) family (9) (10) (11) (12) (13) . Of the Rsk family (Rsk1-4), Rsk2 is a substrate of Erk that has been implicated in mediating Erk (Stat3), p53, and JUN, the protein that forms the activating protein one (AP-1) transcription factor (11) (12) (13) (14) .
Overexpression of Rsk2 has been associated with the development of multiple types of hematological and epithelial malignancies (13) . Rsk2 levels are elevated in more than 50% of breast tumors (14) and its overexpression is associated with shorter disease-free survival (15) . A potential role in cell migration was first proposed when Rsk2 was found to phosphorylate the cytoskeleton-associated protein filamin A (16) . Recently, Rsk2 was identified as an effector of Ras/Erk-mediated EMT and its knockdown reduces metastasis in animal models (17, 18) . A genome-wide mRNA analysis revealed that Erk/Rsk signaling affects the expression of over 50 genes from diverse pathways responsible for cell motility and invasiveness (19) . In addition, a number of growth factors and mitogens, including Egf (20, 21) , insulin (22) , and Igf-1 (23) , are reported to activate Rsk2. Activation Rsk2 stimulates tumor cell motility and invasion by phospho-activation of key transcription factors including Creb, Fos related antigen 1 (Fra1), an oncogenic member of the bZIP family, Stat3, and Fascin, a 55-kDa actin-bundling protein (24) (25) (26) .
The transcription factor Creb has been implicated in tumor promotion and progression and its elevated expression can confer resistance to chemotherapy (25) . Rsk2 can phospho-activate Creb at Ser-133 to promote gene transcription (24) . Creb induces the expression of Stat3 which promotes the transcription of Fascin, which bundles F-actin into parallel arrays to play a central role in Rsk2's inductive influence on the metastatic progression of breast cancer (24, (27) (28) (29) (30) .
Elevated levels of Her2 also drive the expression and/or phospho-activation of Erk1/2, Rsk2, The potential inhibitory impact of the pineal hormone melatonin on the metastatic spread of cancer has been suggested for almost 50 years (32) . Recently, we reported that "tissue-isolated" MCF-7 human breast tumor xenografts grown in circadian intact nude rats (i.e., expressing a robust nocturnal circadian/melatonin signal) exposed to dim light at night (dLAN) showed almost complete melatonin suppression accompanied by high nighttime expression of phosphoactive Erk1/2, Rsk2, Creb, and Stat3, which was blocked when exogenous melatonin was reintroduced during dLAN (33, 34) . Here, we report that pro-invasive and -metastatic signaling pathway(s) such as Her2, Erk1/2, Rsk2, Creb, Stat3, and Fascin, when activated in vitro, also regulate the expression of urokinase plasminogen activator (uPA) and breast cancer metastasis suppressor protein 1 (BRMS-1) mRNA to drive invasion and metastasis in human breast tumor cells. In addition, melatonin induces BRMS1 mRNA expression to repress tumor cell invasion and metastasis in vitro and in vivo. Finally, in vivo studies employing poorly metastatic MCF-7 breast tumor xenografts grown in athymic female nude rats show that exposure to dLAN, via its disruption of the nocturnal circadian melatonin signal, drives the expression and/or phosphoactivation of signaling nodes involved in metastasis including Her2, Her3, Erk1/2, Src, focal adhesion kinase (Fak), Paxcillin (Pax), protein kinase C alpha (Pkcα), Rsk2, Creb, Stat3, and Fascin, all of which were suppressed in complete dark night when melatonin levels were elevated. Her2 variant (HER2.1) and expressing red fluorescent protein (RFP) were generously provided by Dr. Frank E. Jones (Tulane University, New Orleans, LA). All cell lines were cultured in DMEM medium supplemented with 10% FBS (Gibco BRL), 50 mM minimum essential medium non-essential amino acids, 1 mM sodium pyruvate, 2 mM glutamine, 10 mM basal medium eagle, 100 mg/mL streptomycin, and 100 U/mL penicillin. These cell lines were routinely maintained at 37° C in a humidified atmosphere of 5% CO 2 and 95% air. PT67 cells were cultured in DME (Irvine Scientific, Santa Ana, CA) supplemented with 10% into selective media containing 200 μg/ml of G418, which was gradually increased to 1,000 μg/ml in a step-wise manner. Clones expressing RFP were isolated with cloning cylinders (BelArt Products, Pequannock, NJ) by trypsin/EDTA and were amplified and transferred by conventional culture methods in the absence of G418.
Generation of SKBR-3 cells overexpressing a constitutively active myrRSK2
A cDNA encoding a constitutivel active (CA) myrRSK2 (35) was inserted into bicistronic retroviral vector pBMN-I-GFP. SKBR-3/RSK2 cells were generated from SKBR-3 breast cancer cells transduced with retrovirus generated from pBMN-RSK-GFP vector and selected by FACS.
SKBR-3 cells transduced with empty vector (SKBR-3/vector) were similarly generated.
In vitro cell invasion assays
Becton Dickinson BioCoat™ Matrigel™ Invasion Chambers (BD Biosciences, San Jose, CA) were used for the in vitro cell invasion assays according to the manufacturer's protocol.
Briefly, the matrigel-coated chambers were rehydrated in a humidified tissue culture incubator at 37˚ C in a 5% CO 2 atmosphere. Cells (5x10 12:12 lighting schedule were randomly assigned to two groups of 7 mice each and administered either ethanolic water (0.001% ETOH) or melatonin in their nighttime drinking water such that they received approximately 50 µg/ml melatonin daily based on their water intake. This concentration of melatonin simulates the high normal nighttime physiologic levels of melatonin (33) . Animals were sacrificed after 5 weeks, as a number of mice looked stressed, and lungs were harvested in cold PBS and examined microscopically for metastatic foci using a fluorescent microscope (Nikon AZ-100 low power scope) with a fluorescent illuminator and objectives with appropriate filters. Pictures of ten fields were taken from each animal at a 10X magnification and the number of tumor foci per field counted manually. Diurnal plasma melatonin levels (pg/mL; mean ± 1 SD) of naïve, female nude rats (n = 12) maintained initially in the control LD, 12:12 cycle or in the dLAN cycle were measured as previously described (33) . During the course of these studies blood was collected at six circadian time points (0400-, 0800-, 1200-, 1600-, 2000, and 2400-hr) and melatonin levels measured using a radioimmunoassay kit (Alpco, Salem, NH), as previously described (33) .
Athymic nude rats, housing conditions, arterial blood collection, and transplantation of tissue-isolated tumor xenografts
One week following arterial blood collection in the naïve nude rats described above, animals were implanted in a tissue-isolated fashion with MCF-7 human tumor xenografts obtained from the tumor xenografts initially developed in mice, as described previously (33, 34) . Once implanted and as tissue-isolated tumor xenografts reached a palpable size (approximately pea size) they were measured every day for estimated tumor weights, as previously described (33) . 
Protein and mRNA extraction from tumor xenografts and cell lines
Frozen tumors were pulverized and manually homogenized in a 50 mM HEPES (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate, 0.1% sodium deoxycholate, 1 mM Na 3 VO 4 , 100 nM okadaic acid, and 1x protease inhibitor cocktail-Set I (Calbiochem/EMD Biosciences, Billerica, MA). Cells from in vitro studies were harvested and then lysed in a protein extraction buffer containing Tris (50 mM, pH 7. 
Western blot analysis
Protein concentrations of the total cellular protein extracts from tumor xenografts and cell line lysates were determined using the Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). 
Quantitative real-time reverse transcriptase polymerase chain reaction (qPCR) analyses
Performance and optimal annealing temperatures of the PCR primers for uPA and BRMS1
were tested with gradient PCR. An initial DNA denaturation step at 95° C for 5 min was 
Statistical analysis
Data are represented as the mean ± the standard error of the mean. Statistical significance at 95% confidence level was determined by one-way ANOVA followed by Newman-Kuels posthoc test analyses using the Statview software package (SAS Institute, Inc., Cary, NC).
Melatonin serum levels presented in Figure 6C were compared by one-way ANOVA followed by Bonferroni multiple comparison test to evaluate differences (Prism, GraphPad Software, La Jolla, CA). (Fig. 1F) . 
Results

Melatonin inhibits phospho-activation of
Melatonin inhibits the in vitro invasive capacity of SKBR-3 and MCF-7 Her2.1 breast cancer cells.
Given that phospho-activation of Rsk2 at Ser386 by Erk1/2 is associated with breast cancer metastasis, we next examined the effect of melatonin on the in vitro invasive capacity of SKBR-3 and MCF-7 Her2.1 cells using matrigel-coated transwell invasion chamber assays. As seen in (Fig. 2a) and MCF-7 Her2.1 cells by 43% (Fig. 2b) 
Expression of a constitutively active Rsk2 significantly, but not completely, blocks melatonin-mediated inhibition of p-Creb, p-Stat3 and Fascin.
To determine if expression of a constitutively active (CA)-Rsk2 can block the suppressive effects of melatonin on p-Creb, p-Stat3 and t-Fascin expression, we transfected SKBR-3 breast cancer cells with a CA-Rsk2, as previously described (35) . As seen in Figure 4B Reportedly, Rsk2, via its phospho-activation of Stat3, can inhibit the transcription of the breast cancer metastasis suppressor protein Brms1 gene while inducing Fascin expression to stimulate uPA gene transcription (38) . Thus, we asked if melatonin is able to regulate uPA and BRMS1 mRNA expression in SKBR-3 and MCF-7 Her2.1 cells. Figure 5 shows that melatonin represses uPA mRNA expression but induces BRMS1 mRNA expression in a dose-dependent manner in SKBR-3 cells. The most effective dose of melatonin (10 -9 M) was able to inhibit uPA mRNA expression by 80%, while inducing the levels of BRMS1 by 87%.
dLAN-induced disruption of the circadian melatonin signal promotes an EMT phenotype in tissue-isolated MCF-7 human breast tumor xenografts grown in female athymic nude rats.
We evaluated the effect of circadian/melatonin on MCF-7 tissue-isolated breast tumor xenografts on nude rats housed in a dLAN or LD, 12:12 photo-schedule harvested at 2400 h (12 midnight) by Western blot analysis for the expression of markers of EMT and metastasis.
Melatonin serum levels are presented in Figure 6A . As shown in Figure 6B , exposure to dLAN repressed the expression of t-E-Cadherin, an epithelial cell marker, but induced the expression of mesenchymal cell markers including p-Rsk2, t-Vimentin, t-β-Catenin, and t-Snail.
We have reported that MCF-7 breast tumor xenografts in athymic nude rats exposed to dLAN show increased expression of key signaling pathways (Erk1/2, cSrc, Fak, and Pax) involved in the metastatic progression of breast cancer (33, 34 ). In the current study, we evaluated MCF-7 breast tumor xenografts from nude rats circadian/melatonin disrupted by dLAN and harvested at 2400 h for the expression of makers of EMT and metastasis. However, tumors isolated at midnight (elevated endogenous melatonin) from rats housed under a LD, 12:12 photo-schedule showed elevated expression of E-Cadherin but decreased expression of tVimentin, t-β-Catenin, and t-Snail.
In Figure 6C , MCF-7 breast tumor xenografts isolated from nude rats housed in a dLAN or a LD, 12:12 photo-schedule were harvested at 2400 h (12 midnight) and further evaluated by polymerization (13, 14, (39) (40) (41) (42) (43) . Activation of these same signaling pathways is also seen in breast tumors from patients that have developed resistance to chemotherapy (24, 25) .
We recently reported that disruption of the circadian/melatonin signal by dLAN promotes the expression/phospho-activation of mitogenic and survival pathways associated with the development of drug resistance in ERα-positive breast tumor xenografts, including Erk1/2, Akt, cSrc, Fak, Pax, Creb, and Stat3 (33, 34) . In earlier studies, we reported that melatonin demonstrates potent anti-invasive actions in breast cancer cells in vitro that were mediated, in part, via its repression of p38 Mapk phosphorylation (36) , and the circadian gating of Gsk3β activity (44) . Melatonin phospho-activation of Gsk3β promotes the phosphorylation and 
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The role of p-Erk1/2 and p-Rsk2 in driving the invasive/metastatic potential of SKBR-3 and MCF-7Her2.1 cells is demonstrated by the ability of melatonin to suppress their phospho-activation as well as the invasive capacity of these two cell lines in matrigel-coated transwell assays (Fig.   2) . Melatonin also showed a greater anti-invasive action in SKBR-3 cells as compared to MCF-7 Her2.1 cells. The reason(s) for this difference is currently not clear, but may relate to the fact that SKBR-3 cells endogenously express elevated levels of Her2 to drive Erk1/2 and Rsk2 expression/activation, while MCF-7 Her2.1 cells have been modified to express a constitutively active Her2 mutant. Other differences may be related to the fact that MCF-7 Her2.1 cells are ERα-positive while SKBR-3 cells are ERα-negative, or to differences in the levels of MT 1 receptor expressed in each line. What is clear, however, is that both cell lines express MT 1 receptors (46) and are responsive to melatonin-mediated inhibition of p-Rsk2, p-Creb, p-Stat3, and t-Fascin expression.
Although the anti-invasive actions of melatonin in breast cancer have been reported (36, 44, 47) , we have not yet determined if melatonin actually suppress the complex process of metastasis. We show in figure 3 , that nighttime administration of melatonin to mice with metastatic MCF-7 Her2.1-RFP breast tumor xenografts significantly (p<0.05) suppresses the development of RFP-labeled metastatic foci in the lungs, demonstrating the full anti-metastatic actions of melatonin. Given that these tumor xenografts originated in the mammary fat pad, it is clear that the metastatic cells that colonized the lungs of these mice had to go through the entire process of metastasis. At present we do not yet know if melatonin inhibits a specific aspect or multiple aspects of metastasis; this will be addressed in future studies.
We previously reported (36) and now confirm that melatonin significantly inhibits this invasive/metastatic phenotype via suppression of EMT, either by promoting mesenchymal confirming that Erk is a major upstream node in this signaling pathway that drives metastasis.
However, the ability of melatonin to suppress the expression of p-Creb and p-Stat3 to a greater degree than UO126, combined with the fact that the combination of melatonin and UO126 was more efficacious at inhibiting p-Creb, p-Stat3, and t-Fascin than either agent alone, implies that at least some of the anti-metastatic effects of melatonin may be mediated independent of Rsk2.
This concept is also supported by the ability of melatonin to partially block the expression of pCreb, p-Stat3 and t-Fascin in SKBR-3 cells expressing a CA-Rsk2 construct (Fig. 4B ).
Our studies confirm that activation of the Rsk2/Stat3/Fascin pathway can promote the expression of uPA mRNA (a known activator of MMP 2 and 9 and α4β5 integrin) and inhibit the expression of the breast cancer metastasis suppressor, BRMS1 (Fig. 4) . Interestingly, a consistent but opposite, dose-response effect of melatonin on the expression of uPA and BRMS1 mRNA was evident, with the physiological concentration of melatonin (1 nM) being more effective than higher concentrations for inhibiting uPA and inducing BRMS1 mRNA expression in SKBR-3 cells. This unusual dose response, also observed in our analysis of phospho-activated Erk1/2 and Rsk2, is consistent with our earlier report of the bell-shaped dose-dependent growth- The importance of the circadian/melatonin signal in suppressing the growth and invasive progression of breast and other cancers has been reported by us (36, 46) and others (47, 50) . by inhibiting other mechanisms/pathways that promote metastasis. These data strongly support the concept that exposure to dLAN, with its disruption of the circadian/melatonin signal, promotes EMT and, over time, could generate an enhanced metastatic phenotype in breast tumors.
The fact that some breast cancer cells do not express the MT1 receptor and may be unresponsive to melatonin is important given the potent anti-cancer and anti-metastatic actions of melatonin. We would predict that cancer cells that do not express the MT1 receptor may still respond to melatonin, particularly high physiologic or pharmacologic concentrations of melatonin, and that a melatonin may promote antioxidant mechanisms. However, it is most likely that cells that do not express the MT1 receptor or respond to melatonin may show significantly enhanced tumor growth, progression, and metastatic spread.
These data, combined with our earlier in vitro studies by Mao et al. (36) , support the concept that an extended duration of nocturnal melatonin production plays a critical role in suppressing the metastatic progression of breast cancer. Given the ability of dLAN to inhibit the nocturnal rise of melatonin in the blood and its associated induction of the expression and/or phosphoactivation of various oncogenes including Akt, Her2, Ras, and cSrc (33, 34, 44) , we now consider dLAN to be a key environmental promoter of metastasis. In this regard, dLAN, via its disruption of the circadian/melatonin signal, may represent a unique and previously unappreciated environmental risk factor that could account for the increasingly large number of patients presenting with more aggressive and metastatic breast cancer, leading to a shortened survival time and increased morbidity and mortality. 
